One of Utah’s leading medical technology companies, Myriad Genetics, is settling lawsuits related to several of its patents on genes related to breast and ovarian cancers, opening up competition it has not seen in nearly 15 years. Following an adverse appeals court ruling, Salt Lake City-… [More]

  Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cancer, ending a dispute that was the subject of a landmark Supreme Court ruling that human genes cannot be patented. The company has settled or is in the process of se… [More]

  After months of complaints from the pharmaceutical industry, the U.S. Patent and Trademark Office has issued revised guidelines for its examiners that should make it easier for drug makers and biotechs to obtain patents for their inventions. In general, the new guidelines take what the ag… [More]

  Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad’s gene-based cancer test, the latest setback for the diagnostics company. Myriad’s shares fell 12 percent before the bell on Tuesday.   Myri… [More]

Following the Supreme Court’s rejection of gene patents, the U.S. proposes steep cuts to reimbursements for breast cancer-gene tests.     That natural human genes cannot be patented was one of the biggest biotechnology stories of 2013 and the effects of that Supreme Court decisi… [More]

TANIA SIMONCELLI: Gene patent foe A US science-policy expert fought to keep genes open to all. In 2005, Tania Simoncelli managed to shock the senior lawyer at the American Civil Liberties Union (ACLU). Simoncelli, the organization’s first science adviser, informed him that companies were s… [More]

In the wake of a case that went all the way to the U.S. Supreme Court, Salt Lake City-based Myriad Genetics is now enveloped in a new spate of lawsuits over its gene patents, this time sparring with companies that want to erode its dominant position in testing of genes related to breast and ov… [More]

In June the U.S. Supreme Court ruled that patents on genes were invalid. Yet corporate intellectual-property claims can still harm patients. The court struck down patents held by Myriad Genetics on two human genes linked to breast and ovarian cancers, BRCA1 and BRCA2. The decision ended the c… [More]

The National Institutes of Health should use its march-in rights under the Bayh-Dole Act to force Myriad Genetics Inc. to license its patents related to testing for genetic mutations associated with breast and ovarian cancer, according to a July 12 letter sent by Sen. Patrick J. Leahy … [More]

In the war against inequality, we’ve become so used to bad news that we’re almost taken aback when something positive happens. And with the Supreme Court having affirmed that wealthy people and corporations have a constitutional right to buy American elections, who would have exp… [More]